Amelioration of DSS-Induced Acute Colitis in Mice by Recombinant Monomeric Human Interleukin-22

다국어 초록 (Multilingual Abstract)

IL-22, a pleiotropic cytokine, is known to have a profound effect on the regeneration of damaged intestinal barriers. The tissue-protective properties of IL-22 are expected to be potentially exploited in the attenuation and treatment of colitis. However, because of the disease-promoting role of IL-22 in chronic inflammation, a comprehensive evaluation is required to translate IL-22 into the clinical domain. Here, we present the effective production of soluble human IL-22 in bacteria to prove whether recombinant IL-22 has the ability to ameliorate colitis and inflammation. IL-22 was expressed in the form of a biologically active monomer and non-functional oligomers. Monomeric IL-22 (mIL-22) was highly purified through a series of 3 separate chromatographic methods and an enzymatic reaction. We reveal that the resulting mIL-22 is correctly folded and is able to phosphorylate STAT3 in HT-29 cells. Subsequently, we demonstrate that mIL-22 enables the attenuation of dextran sodium sulfate-induced acute colitis in mice, as well as the suppression of pro-inflammatory cytokine production. Collectively, our results suggest that the recombinant mIL-22 is suitable to study the biological roles of endogenous IL-22 in immune responses and can be developed as a biological agent associated with inflammatory disorders.

참고문헌 (Reference)

1 Collins P, "Ulcerative colitis : diagnosis and management" 333 : 340-343, 2006

2 Ungaro R, "Ulcerative colitis" 389 : 1756-1770, 2017

3 Pithadia AB, "Treatment of inflammatory bowel disease(IBD)" 63 : 629-642, 2011

4 Sabat R, "Therapeutic opportunities of the IL-22-IL-22R1 system" 13 : 21-38, 2014

5 Saxton RA, "The tissue protective functions of interleukin-22 can be decoupled from pro-inflammatory actions through structure-based design" 54 : 660-672, 2021

6 Keir M, "The role of IL-22 in intestinal health and disease" 217 : e20192195-, 2020

7 Lücke J, "The good and the bad about separation anxiety : roles of IL-22 and IL-22BP in liver pathologies" 43 : 591-607, 2021

8 Kane SV, "Systematic review : adherence issues in the treatment of ulcerative colitis" 23 : 577-585, 2006

9 Jones BC, "Structure of IL-22 bound to its high-affinity IL-22R1 chain" 16 : 1333-1344, 2008

10 Ray K, "Stem cells : IL-22 activates ISCs for intestinal regeneration" 13 : 64-, 2016

11 Loera-Arias MJ, "Secretion of biologically active human interleukin 22(IL-22)by Lactococcus lactis" 36 : 2489-2494, 2014

12 Pickert G, "STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing" 206 : 1465-1472, 2009

13 Rosano GL, "Recombinant protein expression in Escherichia coli : advances and challenges" 5 : 172-, 2014

14 Zenewicz LA, "Recent advances in IL-22 biology" 23 : 159-163, 2011

15 Rothenberg ME, "Randomized phase I healthy volunteer study of UTTR1147A(IL-22Fc) : a potential therapy for epithelial injury" 105 : 177-189, 2019

16 Niv-Spector L, "Preparation and characterization of mouse IL-22 and its four single-amino-acid muteins that act as IL-22 receptor-1antagonists" 25 : 397-404, 2012

17 Stefanich EG, "Pre-clinical and translational pharmacology of a human interleukin-22 IgG fusion protein for potential treatment of infectious or inflammatory diseases" 152 : 224-235, 2018

18 Cox JH, "Opposing consequences of IL-23 signaling mediated by innate and adaptive cells in chemically induced colitis in mice" 5 : 99-109, 2012

19 Yu L, "Molecular characteristics of rhesus macaque interleukin-22 : cloning, in vitro expression and biological activities" 154 : 651-662, 2018

20 Qiu Y, "Lactobacillus plantarum enhanced IL-22 production in natural killer(NK)cells that protect the integrity of intestinal epithelial cell barrier damaged by enterotoxigenic Escherichia coli" 18 : 2409-, 2017

21 Colonna M, "Interleukin-22-producing natural killer cells and lymphoid tissue inducer-like cells in mucosal immunity" 31 : 15-23, 2009

22 Lejeune D, "Interleukin-22(IL-22)activates the JAK/STAT, ERK, JNK, and p38 MAP kinase pathways in a rat hepatoma cell line. Pathways that are shared with and distinct from IL-10" 277 : 33676-33682, 2002

23 Parks OB, "Interleukin-22 signaling in the regulation of intestinal health and disease" 3 : 85-, 2016

24 Mihi B, "Interleukin-22 signaling attenuates necrotizing enterocolitis by promoting epithelial cell regeneration" 2 : 100320-, 2021

25 Zhang X, "Interleukin-22 regulates the homeostasis of the intestinal epithelium during inflammation" 43 : 1657-1668, 2019

26 Lindemans CA, "Interleukin-22 promotes intestinal-stem-cell-mediated epithelial regeneration" 528 : 560-564, 2015

27 Kim K, "Interleukin-22 promotes epithelial cell transformation and breast tumorigenesis via MAP3K8 activation" 35 : 1352-1361, 2014

28 Powell N, "Interleukin-22 orchestrates a pathological endoplasmic reticulum stress response transcriptional programme in colonic epithelial cells" 69 : 578-590, 2020

29 Gao B, "Interleukin-22 from bench to bedside : a promising drug for epithelial repair" 16 : 666-667, 2019

30 de Oliveira Neto M, "Interleukin-22 forms dimers that are recognized by two interleukin-22R1receptor chains" 94 : 1754-1765, 2008

31 Shohan M, "Interleukin-22 and intestinal homeostasis : protective or destructive" 72 : 1585-1602, 2020

32 Dudakov JA, "Interleukin-22 : immunobiology and pathology" 33 : 747-785, 2015

33 Xie MH, "Interleukin(IL)-22, a novel human cytokine that signals through the interferon receptor-related proteins CRF2-4 and IL-22R" 275 : 31335-31339, 2000

34 Zenewicz LA, "Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease" 29 : 947-957, 2008

35 Zenlea T, "Immunosuppressive therapies for inflammatory bowel disease" 20 : 3146-3152, 2014

36 Eken A, "IL-23R+ innate lymphoid cells induce colitis via interleukin-22-dependent mechanism" 7 : 143-154, 2014

37 Zindl CL, "IL-22-producing neutrophils contribute to antimicrobial defense and restitution of colonic epithelial integrity during colitis" 110 : 12768-12773, 2013

38 Tsai PY, "IL-22 upregulates epithelial claudin-2 to drive diarrhea and enteric pathogen clearance" 21 : 671-681, 2017

39 Zhang Y, "IL-22 promotes tumor growth of breast cancer cells in mice" 12 : 13354-13364, 2020

40 Ma HL, "IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation" 118 : 597-607, 2008

41 Brand S, "IL-22 is increased in active Crohn’s disease and promotes proinflammatory gene expression and intestinal epithelial cell migration" 290 : G827-G838, 2006

42 Wolk K, "IL-22 increases the innate immunity of tissues" 21 : 241-254, 2004

43 Sugimoto K, "IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis" 118 : 534-544, 2008

44 Ouyang W, "IL-10 family cytokines IL-10 and IL-22 : from basic science to clinical translation" 50 : 871-891, 2019

45 Wei HX, "IL-10 and IL-22 in mucosal immunity : driving protection and pathology" 11 : 1315-, 2020

46 Mizoguchi A, "Healing of intestinal inflammation by IL-22" 18 : 1777-1784, 2012

47 Pham TA, "Epithelial IL-22RA1-mediated fucosylation promotes intestinal colonization resistance to an opportunistic pathogen" 16 : 504-516, 2014

48 Wu T, "Elevated serum IL-22 levels correlate with chemoresistant condition of colorectal cancer" 147 : 38-39, 2013

49 Zhang L, "Disulfide bond formation and its impact on the biological activity and stability of recombinant therapeutic proteins produced by Escherichia coli expression system" 29 : 923-929, 2011

50 Arnau J, "Current strategies for the use of affinity tags and tag removal for the purification of recombinant proteins" 48 : 1-13, 2006

51 Nagem RA, "Crystal structure of recombinant human interleukin-22" 10 : 1051-1062, 2002

52 de Moura PR, "Crystal structure of a soluble decoy receptor IL-22BP bound to interleukin-22" 583 : 1072-1077, 2009

53 Logsdon NJ, "Comparison of interleukin-22 and interleukin-10soluble receptor complexes" 22 : 1099-1112, 2002

54 Mizoguchi A, "Clinical importance of IL-22 cascade in IBD" 53 : 465-474, 2018

55 Monteleone I, "Aryl hydrocarbon receptor-induced signals up-regulate IL-22 production and inhibit inflammation in the gastrointestinal tract" 141 : 237-248, 2011

56 Arab JP, "An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis" 72 : 441-453, 2020

57 Feng Y, "An automatic refolding apparatus for preparative-scale protein production" 7 : e45891-, 2012

58 Xu F, "A rapid bioassay for recombinant interleukin-22" 31 : 71-78, 2010

59 Pelczar P, "A pathogenic role for T cell-derived IL-22BP in inflammatory bowel disease" 354 : 358-362, 2016

60 Arshad T, "A double edged sword role of interleukin-22 in wound healing and tissue regeneration" 11 : 2148-, 2020

61 Kwon J, "A combination strategy of solubility enhancers for effective production of soluble and bioactive human enterokinase" 340 : 57-63, 2021